Nintedanib Halves Annual FVC Decline in Progressive Pulmonary Fibrosis
LUNG function declined more slowly after nintedanib initiation in progressive pulmonary fibrosis patients, according to a nationwide study published in the ERJ Open Res. The retrospective study included 359 patients who started nintedanib at Denmark’s four tertiary interstitial lung disease centers between 2022 and 2024. The median age across the cohort was 72 years. Interstitial … Read more